Mitchell C. Posner to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Mitchell C. Posner has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
2.209
-
Perioperative Gemcitabine?+?Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Ann Surg Oncol. 2019 Dec; 26(13):4489-4497.
Score: 0.323
-
The Italian Collaborative Group sets a standard for the treatment of locally advanced head and neck cancer. Ann Oncol. 2017 09 01; 28(9):2051-2054.
Score: 0.282
-
Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy. Ann Surg Oncol. 2016 06; 23(6):1956-62.
Score: 0.252
-
Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2015 Jul; 22(7):2209-17.
Score: 0.233
-
More harm than good? Ann Surg Oncol. 2014 Sep; 21(9):2817-9.
Score: 0.227
-
A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol. 2012 Feb; 19(2):384-91.
Score: 0.184
-
Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma. Arch Surg. 2001 Jul; 136(7):737-42; discussion 743.
Score: 0.092
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.083
-
Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. Cancer J Sci Am. 1998 Jul-Aug; 4(4):237-46.
Score: 0.075
-
Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018 05 01; 29(5):1130-1140.
Score: 0.074
-
Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck. Ann Oncol. 2014 Aug; 25(8):1667-8.
Score: 0.056
-
A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma. Am J Clin Oncol. 1992 Jun; 15(3):239-41.
Score: 0.049
-
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 01; 29(7):934-43.
Score: 0.045
-
A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. Am J Clin Oncol. 1990 Oct; 13(5):455-8.
Score: 0.044
-
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol. 2011 Dec; 28 Suppl 1:S152-61.
Score: 0.043
-
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol. 2011 Feb; 22(2):348-54.
Score: 0.043
-
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1245-1254.
Score: 0.027
-
Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2001 Nov 01; 51(3):599-604.
Score: 0.024
-
Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol. 1998 Sep; 9(9):1035-7.
Score: 0.019
-
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. Semin Oncol. 1997 Dec; 24(6 Suppl 19):S19-89-S19-92.
Score: 0.018
-
Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma. Am J Clin Oncol. 1995 Aug; 18(4):300-2.
Score: 0.015
-
Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. Eur J Cancer. 1993; 29A(4):511-5.
Score: 0.003